Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
retifanlimab + INCB050465
- Development stage
- Phase 1
- Lead developer
- Incyte
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
A combination of retifanlimab, a humanized IgG4 monoclonal antibody immune checkpoint inhibitor targeting programmed death-1 (PD-1), and INCB050465, a small molecule inhibitor of phosphoinositide 3-kinase delta (PI3Kδ), both developed by Incyte. Retifanlimab works by blocking PD-1 to release immune "brakes" and enhance T cell-mediated antitumor immune activity. INCB050465 inhibits PI3Kδ, a key kinase in B cell and immune modulation signaling, further influencing the tumor microenvironment. This combination is being investigated primarily for antineoplastic effects in advanced solid tumors, with retifanlimab now FDA approved for use with chemotherapy in metastatic squamous cell carcinoma of the anal canal (SCAC).
- Other names
- retifanlimab-dlwrINCB050465INCB-050465INCB 050465Zynyz
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)PIK3CD (Phosphatidylinositol 3-kinase delta)
Beyond the preview
Go deeper on retifanlimab + INCB050465.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on retifanlimab + INCB050465.